The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance

Pulmonary Pharmacology

Volumn 7, Issue 2, 1994, Pages 81-89

  Clarke, W R ^a   Uezono, S ^a   Chambers, A ^a   Doepfner, P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Phosphodiesterase enzymes; Phosphodiesterase inhibitors; Pulmonary hypertension; Pulmonary vascular resistance; Synergism

Indexed keywords

EID: 0028332080     PISSN: 09520600     EISSN: None     Source Type: Journal    
DOI: 10.1006/pulp.1994.1009     Document Type: Article

References (16)

1. Braunwald E. Intravenous milrinone: therapeutic responses in heart failure. Am Heart J 1991; 121: 1937-1938.
2. Colucci W. Cardiovascular effects of milrinone. Am Heart J 1991; 121: 1945-1947.
3. Clarke W R, Morray J P, Powers K, Soltow L O. Amrinone reduces pulmonary vascular resistance elevated by U46619 in isolated perfused lungs. J Cardiovasc Pharmacol 1991; 18: 85-94.
4. Haynes J Jr, Kithas P A, Taylor A E, Strada S J. Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am J Physiol 1991; 261: H487-H492.
5. Francis S H, Thomas M K, Corbin J D. Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from the lung. In: Beavo J, Houslay M D eds. Cyclic nucleotide phosphodiesterases: structure, regulation and drug action, vol 2. West Sussex: Wiley-Interscience, 1990.
6. Thomas M K, Francis S H, Corbin J D. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990; 265: 14964-14970.
7. Fujimoto FC, Sakai A, Yoshikawa S, Shinozaki S, Matasuzawa Y et al. Effect of cyclic guanosine monophosphate on hypoxic and angiotensin-II-induced pulmonary vasoconstriction. Lung 1990; 168: 333-343.
8. Braner D A, Fineman J R, Chang R, Soifer S J. M& B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 1993; 264: H252-H258.
9. Clarke W R, Haberkern C M, Zeh J, Powers K, Sharar S R, Soltow L O. The HPV response is different with constant pressure versus constant flow perfusion. Respir Physiol (in press).
10. Tanaka H, Tajimi K, Moritsune O, Kobayashi K, Okada K. Effects of milrinone on pulmonary vasculature in normal dogs and dogs with pulmonary hypertension. Crit Care Med 1991; 19: 68-74.
11. Berger J I, Gibson R L, Clarke W R, Standaert T A, Redding G J, Henderson W R, Truog W E. Effect of amrinone during group B streptococcus-induced pulmonary hypertension in piglets. Pediatr Pulmonol 1993; 16: 303-310.
12. Degerman E, Manganiello V C, Newman A H, Rice K C, Belfrage P. Purification, properties and polyclonal antibodies for the particulate, low Km cAMP phosphodiesterase from bovine adiopose tissue. Second Messengers Phosphoproteins 1988; 12: 171-182.
13. Burns F, Pyne N J. Interaction of the catalytic subunit of protein kinase A with type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites. Biochem Biophys Res Comm 1992; 189: 1389-1396.
14. Lugnier C, Schoeffter P, LeBec A, Strouthou E, Stoclet J C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986; 35: 1743-1751.
15. 2 adenosine receptors in the skin microcirculation. Circ Res 1989; 65: 176-184.
16. Mustafa S J. Effects of coronary vasodilator drugs on the uptake and release of adenosine in cardiac cells. Biochem Pharmacol 1979; 28: 2617-2624.